



Contact: Paul Sheiffele  
Technologies Inc.  
Phone: 631-881-0844  
Avenue  
Email: [info@hairpintech.com](mailto:info@hairpintech.com)  
11779  
Web: [www.hairpintechnologies.com](http://www.hairpintechnologies.com)

Hairpin  
2200 Smithtown  
Ronkonkoma, NY

---

For Immediate Release:  
January 4, 2016

## **Hairpin Technologies Exceeds \$1M in shRNA Licensing Revenue on Behalf of Cold Spring Harbor Laboratory**

*Commercial Distributor Licensees Include Sigma-Aldrich and Life Technologies/Thermo-Fisher, and End-User Licensees Include Biogen, Epizyme, GlaxoSmithKline, Johnson & Johnson, and ORIC Pharmaceuticals*

**Ronkonkoma, NY; January 4, 2016:** Hairpin Technologies announced today that it has exceeded \$1M in licensing revenue as the exclusive agent of Cold Spring Harbor Laboratory (CSHL) representing their shRNA intellectual property portfolio. Established in March 2015, Hairpin Technologies maintains the sole authority to negotiate and execute license agreements with potential licensees of the relevant U.S. and international patents covering the shRNA technology. The company has executed commercial distributor licenses with Sigma-Aldrich and Life Technologies/Thermo-Fisher, as well as commercial end-user licenses with Biogen, Epizyme, GlaxoSmithKline, Johnson & Johnson, and ORIC Pharmaceuticals.

Invented by Dr. Gregory Hannon, Professor and Howard Hughes Medical Institute Investigator at CSHL, shRNA is a versatile research tool used in functional genomics and drug discovery which can be used to silence target gene expression to help elucidate biological function and identify novel drug targets. The technology is particularly useful in determining the role of specific genes in disease, allowing researchers to observe what happens when these genes are turned off. In addition to determining how these genes function, shRNA may also help scientists identify and validate novel drug targets for which new pharmaceuticals can be developed. The technology is already commercially available from a number of authorized distributors with existing non-exclusive license agreements to make, market and sell shRNA. Pharmaceutical and biotechnology companies of all sizes, as well as contract research organizations which utilize shRNA, are also required to obtain a non-exclusive license from CSHL for approved access to the relevant intellectual property. Hairpin Technologies leads ongoing marketing, corporate outreach and out-licensing efforts on behalf of CSHL.

Mr. Joseph Scaduto, Co-Founder and Managing Partner of Hairpin Technologies, stated, "Our recent success in securing non-exclusive license agreements with commercial distributors and end-users further demonstrates the value and versatility of the shRNA technology, as well as its importance to research and development efforts throughout the pharmaceutical and biotechnology industry." He added, "We fully anticipate that Hairpin Technologies will continue to expand licensing activity throughout 2016."

Ms. Teri Willey, Vice President, Business Development and Technology Transfer at CSHL, commented, "We are very grateful to Hairpin Technologies for representing the shRNA patent portfolio of Cold Spring Harbor Laboratory and for generating this licensing revenue in such a short period of time."

**About Cold Spring Harbor Laboratory:** Celebrating its 125<sup>th</sup> anniversary in 2015, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel

Prize winners, the private, not-for-profit Laboratory is more than 600 researchers and technicians strong. The Meetings & Courses Program hosts more than 12,000 scientists from around the world each year on its campuses in Long Island and in Suzhou, China. The Laboratory's education arm also includes an academic publishing house, a graduate school and programs for middle and high school students and teachers. For more information, visit [www.cshl.edu](http://www.cshl.edu).

**About Hairpin Technologies:** Hairpin Technologies Inc. was founded in 2015 to expand the commercial distribution and research use of short hairpin RNA (shRNA), a versatile biomedical research and drug discovery tool invented at Cold Spring Harbor Laboratory (CSHL). As the exclusive licensing agent of CSHL, the mission of Hairpin Technologies is to negotiate and execute license agreements with manufacturers, distributors and end-users of the shRNA technology, which is protected by a robust portfolio of U.S. and international patents. In this capacity, Hairpin Technologies leads ongoing marketing, corporate outreach and out-licensing efforts to identify and engage potential licensees on behalf of CSHL. For more information, visit [www.hairpintechnologies.com](http://www.hairpintechnologies.com).